155 related articles for article (PubMed ID: 31802311)
1. The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population.
Lisi D; Andrews E; Parry C; Hill C; Ombengi D; Ling H
Cardiovasc Drugs Ther; 2019 Dec; 33(6):755-761. PubMed ID: 31802311
[TBL] [Abstract][Full Text] [Related]
2. Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.
Gilbert BW; Sherard M; Little L; Branstetter J; Meister A; Huffman J
Am J Cardiol; 2018 Feb; 121(4):509-512. PubMed ID: 29274809
[TBL] [Abstract][Full Text] [Related]
3. Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.
Banerjee K; Ghosh RK; Kamatam S; Banerjee A; Gupta A
Int J Cardiol; 2017 Jan; 227():556-564. PubMed ID: 27838121
[TBL] [Abstract][Full Text] [Related]
4. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
[TBL] [Abstract][Full Text] [Related]
5. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice.
Ning Y; Zhen W; Fu Z; Jiang J; Liu D; Belardinelli L; Dhalla AK
J Pharmacol Exp Ther; 2011 Apr; 337(1):50-8. PubMed ID: 21228065
[TBL] [Abstract][Full Text] [Related]
7. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.
Eckel RH; Henry RR; Yue P; Dhalla A; Wong P; Jochelson P; Belardinelli L; Skyler JS
Diabetes Care; 2015 Jul; 38(7):1189-96. PubMed ID: 26049552
[TBL] [Abstract][Full Text] [Related]
8. A New Algorithm Dedicated to Blood Glucose Monitoring in Insulin-Treated Elderly Dependent People With Diabetes.
Grino M; Loundou A; Boucekine M; Alitta Q; Oliver C
J Diabetes Sci Technol; 2019 Mar; 13(2):410-412. PubMed ID: 30537870
[No Abstract] [Full Text] [Related]
9. Diabetes News.
Regier EE; Gao HX; Close KL
J Diabetes; 2015 Nov; 7(6):749-53. PubMed ID: 26223410
[No Abstract] [Full Text] [Related]
10. Antidiabetic potential of saffron and its active constituents.
Yaribeygi H; Zare V; Butler AE; Barreto GE; Sahebkar A
J Cell Physiol; 2019 Jun; 234(6):8610-8617. PubMed ID: 30515777
[TBL] [Abstract][Full Text] [Related]
11. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.
Mihos CG; Krishna RK; Kherada N; Larrauri-Reyes M; Tolentino A; Santana O
Pharmacol Res; 2016 Jan; 103():49-55. PubMed ID: 26546970
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications.
Sun B; Luo Z; Zhou J
Cardiovasc Diabetol; 2021 Jan; 20(1):9. PubMed ID: 33413392
[TBL] [Abstract][Full Text] [Related]
13. Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
Ambrosio G; Tamargo J; Grant PJ
Diab Vasc Dis Res; 2016 Mar; 13(2):98-112. PubMed ID: 26873904
[TBL] [Abstract][Full Text] [Related]
14. The Human Factor: The Cost of Switching from Analog to Human Insulin.
Tsai A
Diabetes Forecast; 2017 Mar; 70(2):44-47. PubMed ID: 29897684
[No Abstract] [Full Text] [Related]
15. Regular mailing of personalized feedback reports improves glycemic control in diabetes: A randomized controlled trial.
Yin J; Luk A; Wong R; Chung H; Kong A; Ozaki R; Ma R; Chow CC; So W; Chan J
J Diabetes; 2017 May; 9(5):536-538. PubMed ID: 28083979
[No Abstract] [Full Text] [Related]
16. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
Sossalla S; Maier LS
Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
18. Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.
Lejeune S; Roy C; Slimani A; Pasquet A; Vancraeynest D; Vanoverschelde JL; Gerber BL; Beauloye C; Pouleur AC
Cardiovasc Diabetol; 2021 Feb; 20(1):48. PubMed ID: 33608002
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine and Its Effects on Hemoglobin A1C.
Greiner L; Hurren K; Brenner M
Ann Pharmacother; 2016 May; 50(5):410-5. PubMed ID: 26917816
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
